Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8447684 | European Journal of Cancer | 2011 | 7 Pages |
Abstract
Introduction of SLND in breast cancer treatment in Denmark has resulted in a stage migration on 4% due to identification of more micrometastases. However, this stage migration has only minor impact on patients offered adjuvant systemic treatment because nodal status today is less important in risk-allocation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Tove Filtenborg Tvedskov, Maj-Britt Jensen, Eva Balslev, Bent Ejlertsen, Niels Kroman,